ArticlePloS one2026
Trends and spatial distribution of low-level viremia among Ugandan children and adolescents, 2014-2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-level viremia (LLV) is as an early warning signal for treatment failure and onward transmission risk. Uganda has achieved major progress in expanding viral load (VL) testing coverage, yet the burden and trends of LLV among children and adolescents living with HIV (CALHIV) remain insufficiently described. This study assessed national LLV prevalence, temporal trends, and regional distribution from 2014-2023 to guide pediatric HIV program planning.
methodsWe analyzed routine VL data from Uganda's Laboratory Information Management System (LIMS) housed at the Central Public Health Laboratories for CALHIV aged 0-19 years with VL results between 2014 and 2023. Viral suppression was defined as <200 copies/mL for plasma and <400 copies/mL for dried blood spot (DBS) samples. LLV was categorized as 201-999 copies/mL for plasma and 401-999 copies/mL for DBS. We analyzed LLV proportions over time and disaggregated them by demographic (age, sex), clinical (ART regimen, duration on ART, adherence, WHO stage), and facility-level (ownership, level of care) characteristics. The Mann-Kendall trend test was used to assess the significance of observed trends.
resultsA total of 974,873 VL tests were analyzed, of which LLV accounted for 14% (138,126). Nationally, LLV increased from 10.5% in 2014 to 16.2% in 2023 (p < 0.001). LLV rose in both males (10.7% to16.9%, p < 0.001) and females (10.3% to15.6%, p = 0.025), with the steepest increase among infants (12.7%to 22.5%, p < 0.001). Increases were observed among CALHIV on first-line regimens (10.2% to15.7%, p < 0.01), those on ART ≥ 5 years (12.5% to17.8%, p < 0.01), and those with good adherence (10.2% to14.9%, p < 0.001). In 2023, five of fifteen regions recorded LLV prevalence above 20%.
conclusionThe rising LLV burden among CALHIV in Uganda signals emerging virologic challenges that may compromise long-term treatment outcomes. Strengthening VL monitoring, early detection of LLV, and tailored adherence interventions are critical to sustaining viral suppression and preventing progression to high-level viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.